GENERAL ASSEMBLY OF NORTH CAROLINA 1993 SESSION

CHAPTER 269 SENATE BILL 500

AN ACT TO REQUIRE PROSTATE-SPECIFIC ANTIGEN (PSA) TEST COVERAGE IN HEALTH AND ACCIDENT INSURANCE POLICIES, IN HOSPITAL OR MEDICAL SERVICES PLANS, AND IN HMO PLANS.

The General Assembly of North Carolina enacts:

Section 1. Chapter 58 of the General Statutes is amended by adding the following new section to read:

"§ 58-51-58. Coverage for prostate-specific antigen (PSA) tests.

(a) Every policy or contract of accident and health insurance, and every preferred provider contract, policy, or plan as defined and regulated under G.S. 58-50-50 and G.S. 58-50-55, that is issued, renewed, or amended on or after January 1, 1994, shall provide coverage for prostate-specific antigen (PSA) tests or equivalent tests for the presence of prostate cancer. The same deductibles, coinsurance, and other limitations as apply to similar services covered under the policy, contract, or plan shall apply to coverage for prostate-specific antigen (PSA) tests or equivalent tests for the presence of prostate-specific antigen (PSA) tests or equivalent tests for the presence of prostate-specific antigen (PSA) tests or equivalent tests for the presence of prostate-specific antigen (PSA) tests or equivalent tests for the presence of prostate-specific antigen (PSA) tests or equivalent tests for the presence of prostate-specific antigen (PSA) tests or equivalent tests for the presence of prostate-specific antigen (PSA) tests or equivalent tests for the presence of prostate-specific antigen (PSA) tests or equivalent tests for the presence of prostate cancer.

(b) As used in this section, 'prostate-specific antigen (PSA) tests or equivalent tests for the presence of prostate cancer' means serological tests for determining the presence of prostate cytoplasmic protein (PSA) and the generation of antibodies to it, as a novel marker for prostatic disease.

(c) <u>Coverage for prostate-specific antigen (PSA) tests or equivalent tests for the</u> presence of prostate cancer shall be provided when recommended by a physician."

Sec. 2. Chapter 58 of the General Statutes is amended by adding the following new section to read:

"<u>§ 58-65-93. Coverage for prostate-specific antigen (PSA) tests.</u>

(a) Every insurance certificate or subscriber contract under any hospital service plan or medical service plan governed by this Article and Article 66 of this Chapter, and every preferred provider contract, policy, or plan as defined and regulated under G.S. 58-50-50 and G.S. 58-50-55, that is issued, renewed, or amended on or after January 1, 1994, shall provide coverage for prostate-specific antigen (PSA) tests or equivalent tests for the presence of prostate cancer. The same deductibles, coinsurance, and other limitations as apply to similar services covered under the certificate or contract shall apply to coverage for prostate-specific antigen (PSA) tests or equivalent tests for the presence of prostate cancer.

(b) As used in this section, 'prostate-specific antigen (PSA) tests or equivalent tests for the presence of prostate cancer' means serological tests for determining the

presence of prostate cytoplasmic protein (PSA) and the generation of antibodies to it, as a novel marker for prostatic disease.

(c) <u>Coverage for prostate-specific antigen (PSA) tests or equivalent tests for the presence of prostate cancer shall be provided when recommended by a physician.</u>"

Sec. 3. Chapter 58 of the General Statutes is amended by adding the following new section to read:

"<u>§ 58-67-77. Coverage for prostate-specific antigen (PSA) tests.</u>

(a) Every health care plan written by a health maintenance organization and in force, issued, renewed, or amended on or after January 1, 1994, that is subject to this Article, shall provide coverage for prostate-specific antigen (PSA) tests or equivalent tests for the presence of prostate cancer. The same deductibles, coinsurance, and other limitations as apply to similar services covered under the plan shall apply to coverage for prostate-specific antigen (PSA) tests for the presence of prostate cancer.

(b) As used in this section, 'prostate-specific antigen (PSA) tests or equivalent tests for the presence of prostate cancer' means serological tests for determining the presence of prostate cytoplasmic protein (PSA) and the generation of antibodies to it, as a novel marker for prostatic disease.

(c) <u>Coverage for prostate-specific antigen (PSA) tests or equivalent tests for the presence of prostate cancer shall be provided when recommended by a physician.</u>"

Sec. 4. G.S. 58-50-155 is amended by adding a new subsection to read:

"(a1) Notwithstanding G.S. 58-50-125(c), the standard health plan developed and approved under G.S. 58-50-125 shall provide coverage for prostate-specific antigen (PSA) tests or equivalent tests for the presence of prostate cancer at least equal to the coverage required by G.S. 58-51-58."

Sec. 5. Nothing in this act shall apply to specified accident, specified disease, hospital indemnity, medicare supplement, or long-term care health insurance policies.

Sec. 6. This act is effective upon ratification.

In the General Assembly read three times and ratified this the 5th day of July, 1993.

Dennis A. Wicker President of the Senate

Daniel Blue, Jr. Speaker of the House of Representatives